Compare Quest Diagnostics Inc (DGX) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI Indonesia ETF — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while iShares MSCI Indonesia ETF trades at $12.41 (market cap $410.85M). The key difference: Quest Diagnostics Inc is far larger — about 61× iShares MSCI Indonesia ETF's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares MSCI Indonesia ETF for 75 Days on average.
| DGX | EIDO | |
|---|---|---|
Market Cap | $25.06B | $410.85M |
Volume | 927,361 | 726,664 |
Sector | Health | — |
52-Week High | $247.45 | $19.22 |
52-Week Low | $173.49 | $10.80 |
Typical Hold Time | 56 Days | 75 Days |
Enterprise Value | $30.82B | — |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces weak price action despite potential valuation appeal. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains.
Outlook remains cautious due to technical downtrend and sector concentration risks. The 44% financials weighting and modest EPS growth constrain upside, though seasonal patterns may offer temporary support. Key risks include regional market volatility and dependence on commodity cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
